TRANSGENE

Transgene's Phase II trial of viral-based vaccine TG4001, combined with Bavencio, failed to meet primary endpoint of PFS in solid tumours, causing a stock drop. However, a positive trend was observed in cervical cancer patients, prompting further analysis. The company remains focused on its personalized cancer vaccine TG4050.

Transgene's TG4001 vaccine for cervical and anogenital cancers failed to meet primary PFS objective in phase 2 trial, but showed a trend towards improvement in cervical cancer subgroup, requiring further analysis. TG4001 uses a Modified Vaccinia virus Ankara vector with HPV E6, E7 antigens, and human IL-2. The company plans a full data analysis before deciding the future of TG4001, while focusing on its other vaccine programs, including TG4050 for head and neck cancer.

Transgene's Phase II study of TG4001 with avelumab in HPV16-positive cervical and anogenital tumors did not meet primary objectives, though a positive trend was observed in cervical cancer patients, requiring further analysis.

Phase 2 trial of TG4001 with avelumab did not meet primary objective in HPV16-positive cervical and anogenital cancers, but showed positive efficacy trend in cervical cancer subgroup. Transgene plans to analyze data before deciding future steps, with results to be presented at a scientific conference.

Transgene's Phase II study of TG4001 with avelumab in HPV16-positive cervical and anogenital tumors did not meet primary objectives. Subgroup analysis showed a positive trend in cervical cancer patients, needing further confirmation. Treatment was well-tolerated with consistent adverse events. Transgene is evaluating study results to determine the next steps.

Transgene's share price dropped 15% after announcing the failure of its Phase II TG4001 trial for cervical and anogenital cancers. The trial did not meet its primary endpoint of improving progression-free survival. Transgene's strategy now focuses on the development of TG4050, a therapeutic vaccine for head and neck cancer.